WO2012040651A3 - Formulations d'opioïdes à libération contrôlée - Google Patents

Formulations d'opioïdes à libération contrôlée Download PDF

Info

Publication number
WO2012040651A3
WO2012040651A3 PCT/US2011/053132 US2011053132W WO2012040651A3 WO 2012040651 A3 WO2012040651 A3 WO 2012040651A3 US 2011053132 W US2011053132 W US 2011053132W WO 2012040651 A3 WO2012040651 A3 WO 2012040651A3
Authority
WO
WIPO (PCT)
Prior art keywords
controlled release
opioids
release formulations
opioid
methods
Prior art date
Application number
PCT/US2011/053132
Other languages
English (en)
Other versions
WO2012040651A2 (fr
Inventor
Edward M. Rudnic
Michael Vachon
Gary W. Pace
Joseph Berry
Felix De La Iglesia
Original Assignee
QRxPharma Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/024,319 external-priority patent/US20110195989A1/en
Application filed by QRxPharma Ltd. filed Critical QRxPharma Ltd.
Priority to EP11764653.9A priority Critical patent/EP2618820A2/fr
Priority to AU2011305161A priority patent/AU2011305161A1/en
Priority to JP2013530379A priority patent/JP2013537915A/ja
Priority to CA2812570A priority patent/CA2812570A1/fr
Priority to CN2011800562785A priority patent/CN103476403A/zh
Publication of WO2012040651A2 publication Critical patent/WO2012040651A2/fr
Publication of WO2012040651A3 publication Critical patent/WO2012040651A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Abstract

La présente invention concerne des formulations pharmaceutiques contenant des composants opioïdes qui possèdent chacun un profil de libération. Ces composants peuvent procurer une libération immédiate ou contrôlée de l'opioïde. L'invention a également trait à des procédés de régulation de la libération d'un ou de plusieurs composés opioïdes et à des méthodes de traitement de la douleur.
PCT/US2011/053132 2010-09-24 2011-09-23 Formulations d'opioïdes à libération contrôlée WO2012040651A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP11764653.9A EP2618820A2 (fr) 2010-09-24 2011-09-23 Formulations d'opioïdes à libération contrôlée
AU2011305161A AU2011305161A1 (en) 2010-09-24 2011-09-23 Controlled release formulations of opioids
JP2013530379A JP2013537915A (ja) 2010-09-24 2011-09-23 オピオイドの制御放出製剤
CA2812570A CA2812570A1 (fr) 2010-09-24 2011-09-23 Formulations d'opioides a liberation controlee
CN2011800562785A CN103476403A (zh) 2010-09-24 2011-09-23 阿片样物质的控释制剂

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38622710P 2010-09-24 2010-09-24
US61/386,227 2010-09-24
US13/024,319 US20110195989A1 (en) 2010-02-09 2011-02-09 Controlled Release Formulations of Opioids
US13/024,319 2011-02-09

Publications (2)

Publication Number Publication Date
WO2012040651A2 WO2012040651A2 (fr) 2012-03-29
WO2012040651A3 true WO2012040651A3 (fr) 2012-05-18

Family

ID=44741728

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/053132 WO2012040651A2 (fr) 2010-09-24 2011-09-23 Formulations d'opioïdes à libération contrôlée

Country Status (6)

Country Link
EP (1) EP2618820A2 (fr)
JP (1) JP2013537915A (fr)
CN (1) CN103476403A (fr)
AU (1) AU2011305161A1 (fr)
CA (1) CA2812570A1 (fr)
WO (1) WO2012040651A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
ATE495732T1 (de) 2003-03-26 2011-02-15 Egalet As Morphin-system mit kontrollierter freisetzung
EP2155167A2 (fr) 2007-06-04 2010-02-24 Egalet A/S Compositions pharmaceutiques à libération contrôlée pour un effet prolongé
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
NZ603579A (en) 2009-06-24 2014-02-28 Egalet Ltd Controlled release formulations
WO2013153451A2 (fr) * 2012-04-09 2013-10-17 QRxPharma Ltd. Formulations d'opioïdes à libération contrôlée
CA2877183A1 (fr) 2012-07-06 2014-01-09 Egalet Ltd. Compositions pharmaceutiques de dissuasion d'abus a liberation controlee
EP3169315B1 (fr) * 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Forme posologique remplie de liquide anti-abus à libération immédiate
CN114515282B (zh) * 2020-11-19 2023-09-08 山东大学 Sorbic acid在制备抗冠状病毒感染药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110195989A1 (en) * 2010-02-09 2011-08-11 Rudnic Edward M Controlled Release Formulations of Opioids

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20030092724A1 (en) * 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
EP1450824A4 (fr) * 2001-11-02 2005-09-28 Elan Corp Plc Composition pharmaceutique
US8906413B2 (en) * 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
JP2008526846A (ja) 2005-01-05 2008-07-24 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 鎮痛性結合体
JP2008534564A (ja) * 2005-03-28 2008-08-28 オレクソ・アクチエボラゲット 痛みの治療に有用な新しい製薬組成物
US20090082466A1 (en) 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
CA2667259A1 (fr) * 2006-11-07 2008-05-15 Nektar Therapeutics Al, Corporation Formes dosifiees et co-administration d'un agoniste opioide et d'un antagoniste opioide
WO2009143209A1 (fr) * 2008-05-20 2009-11-26 Qrxpharma Limited Thérapie contre la douleur utilisant deux opioïdes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110195989A1 (en) * 2010-02-09 2011-08-11 Rudnic Edward M Controlled Release Formulations of Opioids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
U.S. Provisional Application Ser. No. 61/302,698 filed Feb. 9, 2010 *

Also Published As

Publication number Publication date
CA2812570A1 (fr) 2012-03-29
WO2012040651A2 (fr) 2012-03-29
EP2618820A2 (fr) 2013-07-31
CN103476403A (zh) 2013-12-25
JP2013537915A (ja) 2013-10-07
AU2011305161A1 (en) 2013-05-09

Similar Documents

Publication Publication Date Title
WO2012040651A3 (fr) Formulations d'opioïdes à libération contrôlée
IL207713A0 (en) Formulation and method for the prevention and treatment of bone metastases or other bone diseases
IL225471A0 (en) Preparations and methods for the prevention and treatment of cancer
EP2361089A4 (fr) Compositions et procédés pour le traitement d une fonction altérée de l' -synucléine
ZA201202596B (en) Compounds for the treatment of dyslipidemia and related diseases
IL224544B (en) Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
EP2528603A4 (fr) Compositions pharmaceutiques pour le traitement de la douleur et d'autres indications
IL210810A0 (en) Compositions for the treatment of pain and/or inflamtion
HK1184370A1 (zh) 用於治療疼痛的藥物組合
IL251083A0 (en) Compounds and preparations for the treatment of cancer
EP2558085A4 (fr) Compositions et procédés pour la prévention et le traitement du cancer
IL211313A0 (en) Compounds, compositions and methods for the treatment of ??-amyloid diseases and synucleinopathies
SG10201405392RA (en) Method of treatment of neurodegenerative or neuro-muscular degenerative diseases andtherapeutic agent to treat the same
IL213703A (en) Compounds for the treatment of pain and other diseases
PL2331092T3 (pl) Sposoby i kompozycje do podawania 3-halopirogronianiu i związków pochodnych w leczeniu nowotworu
WO2013153451A3 (fr) Formulations d'opioïdes à libération contrôlée
EP2493305A4 (fr) Composés 2-aminoindoles et méthodes de traitement de la malaria
SG10201403562UA (en) Implant for the treatment or prevention of an aneurysm
GB201008792D0 (en) Apparatus for exfoliating skin and/or for the relief of itches
AU2010904906A0 (en) Methods and compositions for the treatment and prevention of skin disorders
AU2010903965A0 (en) Formulation and method for the treatment of timber
IL221238A0 (en) Pharmaceutical compositions and methods for the treatment and prevention of cancer
HU0800083D0 (en) Pharmaceutical compositions for the treatment and prevention of tumorous diseases
EP2276502A4 (fr) Compositions pour la prévention et le traitement de lésions neurologiques et méthodes d'utilisation associées
AU2008902119A0 (en) Stimulation system for the treatment of tinnitus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11764653

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2013530379

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2812570

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2011764653

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011764653

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011305161

Country of ref document: AU

Date of ref document: 20110923

Kind code of ref document: A